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ABSTRACT
Introduction: Interest is growing in the role of pituitary adenylate cyclase-activating polypeptide 
(PACAP) and its specific PAC1 receptor in migraine and in their antagonism as a strategy for migraine 
prevention.
Areas covered: We discuss and critically evaluate (i) the evidence of the role of PACAP in migraine 
pathophysiology and (ii) the first clinical trials in migraine prophylaxis with monoclonal antibodies AMG 
301 and ALD1910 which act against PAC1 and PACAP38 respectively. We examined PubMed, Scopus, 
and ClinicalTrials.gov electronic databases to examine the relevant material.
Expert opinion: There is much proof of the ability of PACAP to cause migraine, but there is limited 
evidence that blocking PACAP or PAC1 receptor can prevent migraine. However, the potential of anti- 
PACAP antibodies in migraine prophylaxis is high. Theoretically, if these antibodies block the activation 
of the trigeminovascular system, they will prevent the onset of migraine attacks. There are still knowl-
edge gaps in the role of PACAP in migraine and the risk/benefit ratio of anti-PACAP antibodies must be 
carefully studied.
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1. Introduction
Among the most painful and disabling disorders there is 
migraine, which causes a very high load of individual suffering, 
enormous social costs and a strong need for better pharma-
cotherapies. In fact, the treatment of migraine was mainly 
based on nonspecific drugs that are not suitable for all patients 
because of side effects [1]. Migraine is a primary disorder char-
acterized by recurrent attacks of throbbing headache, associated 
with nausea, vomiting, photophobia, and phonophobia [2], 
which affects more than 12% of the general population, with 
a clear prevalence of the female gender [3].
The etiology of migraine is still not fully known; it is 
thought to be a neurovascular disorder characterized by an 
increased cortical excitability, brain stem as generator, the 
origin is perhaps in the hypothalamus, and activator (unclear 
how) of the trigeminovascular system [4].
The activation of trigeminal sensory pathways is thought to 
cause an inflammatory response involving immune, vascular, 
and neuron cells, with release of neuropeptides and pro- 
inflammatory neurotransmitters, which induce a state of sterile 
inflammation in the intracranial meninges, leading to further 
activation of nociceptors and migraine pain [5–8]. Although 
neuroinflammation in the trigeminovascular system does not 
completely explain the onset of the attack, it could be crucial in 
promoting the progression of episodic migraine into a chronic 
form [9]. Various sensory neuropeptides, including calcitonin 
gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), 
and pituitary adenylate cyclase-activating polypeptide (PACAP), 
play an important role in the pathophysiology of migraine [10].
Better understanding these various systems involved in 
migraine pioneered the development and marketing of innova-
tive treatments targeting CGRP [11]. In turn, these recent successes 
have further stimulated the search for novel migraine therapies 
[12]. In particular, ongoing research is focusing on the involvement 
of PACAP in migraine pain. The purpose of this review is to present 
an update on current developments in targeting PACAP for 
migraine prophylaxis. Moreover, we critically discussed this area.
A literature search on migraine and PACAP was performed. The 
electronic databases PubMed, Scopus, and ClinicalTrials.gov were 
used to identify the background and relevant studies (preclinical 
and clinical). In particular, database search was conducted by 
entering the keyword ‘migraine’ in combination with the follow-
ing terms: clinical trial; PACAP; PAC1; PACAP38; PACAP27; prophy-
lactic treatment; trigeminovascular system; VIP; VPAC1; and 
VPAC2. Search results were assessed for their overall relevance 
to this review.
2. PACAP background
PACAP is a neuropeptide that shows very high homology with 
VIP. It belongs to the glucagon/secretin superfamily of pep-
tides (like VIP and secretin) and shares 68% and 37% homol-
ogy of its amino acid sequence with VIP and secretin, 
respectively. Two bioactive forms exist: a 38 amino acid form 
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(PACAP38) and a 27 amino acid form (PACAP27). The amino 
acid sequence of mature human PACAP38 is identical in all 
mammals, suggesting that it was highly conserved during 
evolution [13]. The ADCYAP1 gene, on chromosome 18, 
encodes for a pre-proprotein called ‘prepro-PACAP’ that is 
further metabolized in PACAP38 whose internal cleavage 
leads to the formation of PACAP27 [14]. PACAP is 
a pleiotropic peptide that has been found in the respiratory, 
gastrointestinal, urinary, reproductive, and endocrine systems 
[15]. It is well represented in the central and peripheral ner-
vous system, where it acts as a neuromodulator, immunomo-
dulator, and neurotransmitter [16]. PACAP38 is the most 
frequent form in brain tissue [15]; this polypeptide can cross 
the blood brain barrier (BBB) by active transport, but it is 
rapidly degraded or refluxed into the blood, so a direct effect 
on the central nervous system (CNS), in particular on nocicep-
tion, is more likely due to the activation of an area not 
protected by BBB [17].
G-protein coupled PACAP receptors are PAC1, VPAC1, and 
VPAC2. VPAC1 and VPAC2 bind PACAP38, PACAP27, and VIP 
with approximately equal affinity, while PAC1 has a much 
higher affinity for PACAP38 and PACAP27 [15,18]. These recep-
tors activate adenylyl cyclase producing a cyclic adenylyl 
cyclase monophosphate/protein kinase A cascade, which can 
in turn activate the mitogen-activated protein kinase. The 
PAC1 receptor is also coupled to phospholipase C, which 
stimulates calcium mobilization and protein kinase 
A activation [19]. The PAC1 receptor gene can originate differ-
ent isoforms by an alternative splicing [20].
Immunohistochemical studies confirmed the presence of 
PACAP in critical areas for the pathophysiology of migraine, 
such as the trigeminal system, including the trigeminal gang-
lion (TG) [21] and the trigeminal nucleus caudalis (TNC) [22]; 
moreover PACAP was found in nerve fibers of the dura mater 
and cerebral vessels [23], cervical spinal cord [22], sphenopa-
latine and otic ganglia [24], and in different hypothalamic and 
brainstem nuclei [25,26]. In accordance with the presence of 
the polypeptide, PACAP receptors are distributed in different 
regions of the CNS [27,28].
2.1. Role of PACAP in migraine
Primarily, the ability of PACAP38 to induce headache was 
tested in order to study its role in migraine. In a first study 
[29], ten out of twelve healthy subjects reported headache 
after PACAP38 administration. Subsequently [30], a double- 
blind, randomized, and placebo-controlled study found that 
intravenous administration of PACAP38, but not of placebo, 
caused headache in healthy subjects and migraineurs without 
aura and a migraine-like attack in 58% of migraineurs without 
aura and only in 16% of controls. It was also found a dilatation 
of the middle cerebral artery (MCA) and the superficial tem-
poral artery (STA), recorded by a transcranial Doppler and 
ultrasonography, respectively. A magnetic resonance (MR) 
angiography study infusing PACAP38 in nine healthy volun-
teers showed that 89% of the participants experienced an 
immediate headache and 100% experienced a delayed head-
ache. Furthermore, PACAP38 induced a long-lasting dilatation 
of the extracranial part of the middle meningeal artery (MMA), 
but no dilatation of the MCA. These effects were sensitive to 
sumatriptan injection (6 mg) [31]. In a second MR angiography 
study, PACAP38 infusion induced headache in 73% of 
migraine patients, while VIP infusion induced headache in 
only 18% of patients. Furthermore, PACAP38 provoked long- 
lasting vasodilatation of extracranial arteries (such as MMA 
and STA), but not of intracranial ones (such as MCA) [32]. To 
deepen knowledge on PACAP38 activity, a resting-state func-
tional MR study investigated three networks (salience, sensor-
imotor, and default mode), implicated in cognition, pain 
processing, photo and phonophobia, and emotional proces-
sing, during the early phase of migraine attacks pharmacolo-
gically-induced by PACAP38 and VIP. Only intravenous 
PACAP38 infusion, and not VIP, was associated with changes 
in brain network connectivity, such as increased connectivity 
in areas involved in the salience network and decreased/ 
increased connectivity in areas involved in the sensorimotor 
and default mode network [33]. It was also speculated that 
PACAP38 was involved in the development of premonitory 
symptoms of migraine attacks because these symptoms 
appeared after PACAP38 and CGRP infusions in 48% and 9% 
of migraine patients, respectively [34]. Other evidence of 
a connection between migraine and PACAP was the finding 
of higher levels of PACAP38 in the ictal period compared to 
the interictal period [35,36] and the decrease of these levels in 
patients with migraine after sumatriptan administration [36]. 
In addition, two studies reported lower interictal levels of 
PACAP38 in migraineurs than in controls, a phenomenon 
attributed to chronic depletion of PACAP38 caused by an 
excessive consumption during the attacks [35,37]. A clinical 
trial (NCT02542605) evaluated the connections between CGRP 
and PACAP38, blocking CGRP release by its antagonist AMG 
334 (erenumab), but no correlation was reported: hence the 
hypothesis that PACAP38 may represent a unique and distinct 
pathway of migraine [38]. At last, a randomized, double-blind, 
placebo-controlled trial (NCT03881644) has been completed 
to investigate the incidence of headache, migraine attacks, 
and flushing after PACAP38 infusion, with and without treat-
ment with sumatriptan in migraineurs, but it has not been 
published yet. Recently, the infusion of PACAP27 in migraine 
Article highlights
• There is much evidence suggesting a key role of PACAP in the 
PAC1 receptor-mediated activation of the trigeminovascular sys-
tem which is central in the triggering of the migraine attack
• Clinical trials in migraine prophylaxis have been initiated with the 
monoclonal antibodies AMG 301 and ALD1910 which act against 
the PAC1 receptor and PACAP38 respectively
• Anti-PACAP38 or anti-PAC1 antibodies in migraine prevention 
have potential; theoretically, if these antibodies demonstrate the 
capacity to block trigeminovascular system activation, they should 
be capable of preventing the onset of migraine attacks
• To utilize anti-PACAP drugs in migraine prophylaxis, their long- 
term safety must be examined and clarified. Moreover, their 
advantages should be compared with those of the anti-CGRP 
monoclonal antibodies that are available
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patients provoked in a crossover study significantly more 
migraine-like attacks than placebo, further strengthening the 
role of PACAP in the pathogenesis of migraine [39].
Considering that PAC1 receptors are more selective for 
PACAP than VPAC1 and VPAC2 receptors, it was hypothesized 
that PACAP38-induced migraine was mediated by the PAC1 
receptor and caused by prolonged vasodilatation of extracra-
nial vessels [18], perhaps due to mast-cell degranulation [40– 
42]. However, two provocation studies in humans with 
PACAP38 infusion found no increase in markers for mast cell 
degranulation (serum tryptase and tumor necrosis factor 
alpha) [32,43].
PACAP could be involved in the activation/sensitization of 
the trigeminovascular system, too. Indeed, the TG and the TNC 
contain PACAP38 [21,22] and PACAP38 receptors are present 
in the cranial ganglia with perivascular nerve projections [27]. 
Furthermore, PACAP27 and PACAP38 concentrations 
increased in the TNC of rats after electrical or chemical stimu-
lation of the trigeminovascular system [44]. In the rat, the 
administration of a PAC1 receptor antibody, AMG 301, inhib-
ited the stimulus-evoked nociceptive activity in the TNC [45]. 
PACAP38 but not VIP activated trigeminocervical neurons [46]. 
In experimental animal models, intrathecal administration of 
capsaicin resulted in high levels of PACAP27 and PACAP38 in 
the cerebrospinal fluid, supporting the hypothesis of a central 
effect of PACAP38 [47]. Intrathecal administration of PACAP6- 
38, a PAC1 antagonist, reduced mechanical and thermal 
hyperalgesia [48]. In another study, the same PAC1 antagonist 
increased dynorphin release, while PACAP38 administration 
decreased dynorphin release [49]. In accordance with these 
results, PAC1 receptor knockout mice showed reduced noci-
ceptive responses to different stimuli [50].
2.2. Targeting PACAP in migraine prophylaxis
The exact mechanisms of PACAP38-induced migraine are still 
unknown; however, a lot of evidence suggests that this poly-
peptide plays a key role on migraine. Therefore, inhibition of 
PACAP38 could be an effective option for migraine treatment, 
so two strategies were attempted: blocking the PAC1 receptor 
or PACAP38 itself.
Using a monoclonal antibody against the PAC1 receptor, 
AMG 301, a phase 2a, randomized, double-blind, placebo- 
controlled, 3-arm, and parallel group clinical trial 
(NCT03238781) was completed to evaluate efficacy and safety 
in migraine prophylaxis during a 12 week double-blind treat-
ment period. In particular, the effect of AMG 301 on the 
change from the baseline period in monthly migraine days 
was compared to placebo. Participants were randomized 4:3:3 
to placebo, AMG 301 210 mg Q4W or AMG 301 420 mg Q2W, 
respectively. From the results reported in ClinicalTrials.gov, no 
statistically significant differences were found between AMG 
301 and placebo for primary and secondary outcomes. The 
most common adverse events were nasopharyngitis (9.62% 
and 6.86% for 210 mg and 420 mg, respectively, versus 
9.49% for placebo), fatigue (4.81% and 8.82% for 210 mg 
and 420 mg, respectively, versus 5.84% for placebo), influenza 
(4.81% and 5.88% for 210 mg and 420 mg, respectively, versus 
3.65% for placebo), and constipation (3.85% and 5.88% for 
210 mg and 420 mg, respectively, versus 0% for placebo). 
Only 3 patients receiving AMG 301 reported severe treatment- 
emergent adverse events (versus 3 receiving placebo); no fatal 
events were reported.
The antagonist properties of ALD1910, a monoclonal anti-
body 4000-fold more selective for PACAP38 and PACAP27 
than VIP, were tested in an umbellulone-induced rat model 
of headache. Umbellulone acts on the TRPA1 receptor, indu-
cing neurogenic vasodilation (clinically evident as an increase 
in the animal’s facial temperature) and parasympathetic lacri-
mation. ALD1910 led to a dose-dependent inhibition of 
umbellulone-induced neurogenic vasodilatation and parasym-
pathetic lacrimation [51]. At last, a first-in-human, randomized, 
double-blind, and placebo-controlled study in a healthy popu-
lation is ongoing to determine the safety and tolerability of 
ALD1910 (NCT04197349).
3. Conclusion
Intravenous infusion of PACAP38 induces migraine in healthy 
volunteers and triggers delayed migraine-like headaches in 
most migraine patients [30,34,52]. This effect and PACAP38’s 
role in experimental models of neurogenic inflammation indir-
ectly demonstrated that it is involved in activating the trige-
minovascular system. This polypeptide is the most 
represented PACAP isoform in the brain regions associated 
with migraine [52]. Based on this evidence, treatments with 
monoclonal antibodies targeting PACAP or its receptor are 
being developed. These include ALD1910, developed by 
Alder BioPharmaceuticals, which targets the peptide and 
began a first-in-human, randomized, double-blind, and pla-
cebo-controlled study (NCT04197349) in a healthy population 
in October 2019 and AMG 301, developed by Amgen Inc., 
which targets the PAC1 receptor [20,51]. Recently, AMG 301 
completed a phase 2a controlled trial (NCT03238781) in 
migraine prevention, whose results were unfortunately 
unsatisfactory.
Despite the initial failure, the potential of anti-PACAP anti-
bodies in migraine prophylaxis remains high. Theoretically, if 
these antibodies block the activation of the trigeminovascular 
system, they will completely prevent the onset of migraine 
attacks. In addition, monoclonal antibodies should not exhibit 
pharmacokinetic drug-drug interactions, which is optimal for 
migraine prophylaxis, as migraine patients are subject to poly-
pharmacy [53]. However, differences in the release of PACAP 
and CGRP induced by 60 mM potassium or capsaicin were 
recently examined in a rat migraine model. PACAP has been 
observed to be released only within the TG, but not from 
sensory fibers in the dura mater, as occurred for CGRP. These 
data suggest that anti-PACAP antibodies, unable to penetrate 
BEE, may not reach their central targets and thus could be 
ineffective in treating migraine [54]. In any case, bearing in 
mind that PACAP has vital functions, the risk/benefit ratio of 
anti-PACAP antibodies must be carefully studied.
At the time of this review, there is abundant evidence of 
PACAP’s ability to cause migraine, but there is little proof that 
blocking PACAP or its PAC1 receptor can prevent migraine. In 
some ways, PACAP research resembles nitrous oxide (NO) 
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studies. NO donor drugs cause migraine. For example, the 
administration of nitroglycerin, a NO donor, has been widely 
used as a human experimental model of migraine [55]. 
However, selective NOS inhibitors were found to be ineffective 
in acute and preventive treatment of migraine [55,56]. Now, 
the opposite hypothesis is being tested, i.e., that the increase 
in local and systemic NO levels may have therapeutic potential 
in preventive treatment for episodic migraine (NCT03488563). 
However, all the studies carried out are helpful to increase 
knowledge on the pathophysiology of migraine, even if they 
do not lead to the development of drugs for clinical use.
4. Expert opinion
The idea of blocking PACAP or its specific receptor PAC1 to 
prevent migraine follows the winning path that led to the 
development of CGRP antagonists but has not yet produced 
the same success. Unfortunately, the results of the phase 2a 
trial (NCT03238781, reported in clinicaltrial.gov and not yet 
published) with the anti-PAC1 monoclonal antibody, AMG 
301, in migraine prophylaxis are unsatisfactory. To explain 
this failure, Hoffman et al. [45] suggested that AMG 301 
could be useful specially in patients who have autonomic 
symptoms associated with the migraine attack, while in this 
trial the stratification of the patients based on this character-
istic was not performed. The poor results cast doubts on the 
role of the PAC1 receptor as a mediator of PACAP’s migraine 
provocation action. Speculatively, other reasons for failure 
may have been an insufficient or incomplete occupation of 
PAC1 receptors by AMG 301 on all the different receptor iso-
forms or an increased activation of VPAC1 and VPAC2 recep-
tors against the blockade of PAC1, or even the activation of 
the PAC1 receptor by VIP.
In theory the block of endogenous PACAP should not allow 
the activation of migraine attacks. ALD1910 is 4000 times 
more selective for PACAP38 and 27 than for VIP and its 
antagonist activity was dose-dependent in an in vivo animal 
model [51]. However, VIP and PACAP have several shared 
functions [57]. Intravenous infusion of VIP prolonged for 
2 hours induced delayed headache and extracranial vasodila-
tion in healthy volunteers [58]. It cannot be excluded that VIP 
may replace PACAP on all 3 of its receptors, equally causing 
the migraine attack.
Despite the beginning of the clinical phase, research on 
PACAP in migraine still presents areas of uncertainty that 
should be clarified. We are still far from understanding the 
full range of mechanisms that could involve PACAP and its 
receptors in triggering, evolving, and extinguishing the 
migraine attack. However, it bodes well that research is focus-
ing more than ever on the molecular mechanisms of these 
processes [59]. First, the role of the PAC1 receptor as 
a mediator of PACAP’s ability to cause migraines is uncertain. 
Second, the functions in migraine of VPAC1 and VPAC2 recep-
tors, which have similar affinities for PACAP and VIP, have not 
yet been studied in depth. However, all PACAP/VIP receptors 
are present in sensory neurons and vascular smooth muscle 
related to the trigeminovascular system [60]. Furthermore, 
although the substances that cause migraine are normally 
vasodilators and both PACAP and VIP are vasoactive peptides, 
dilation of arterial vessels is not the only factor behind 
migraine [61]. In order to trigger the migraine attack, activa-
tion of the trigeminovascular system is believed to be essen-
tial [62,63]. Endogenous PACAP was proposed just as the 
mediator of this action, whose mechanisms, however, have 
not yet been clarified [59]. Besides, the existence of specific 
PACAP signaling circuits involved in the induction of migraine 
is still being investigated [10].
Surprisingly, we have found no published attempts to pre-
dict the possible risks to which migraine patients could be 
exposed due to long-term blockade of endogenous PACAP or 
its specific PAC1 receptor. Yet, PACAP is a pleiotropic neuro-
peptide that has critical roles in the regulation of stress 
responses [64] and a plethora of vital functions (some of 
those recently studied are listed in Table 1). It influences 
neurotransmission and neuromodulation and has an inhibitory 
effect on neurogenic inflammation and a protective one in 
neuronal ischemic lesions [65,66]. PACAP intervenes in the 
regulatory mechanisms of the gastrointestinal, cardiovascular, 
reproductive, and respiratory systems and in nociceptive pro-
cesses [67]. Finally, the use of analogues or long-lasting PACAP 
agonists is advocated for the treatment of various disorders 
(Table 2), rather than blockade.
Table 1. Some of the PACAP functions recently explored.
Target Function References
Reproduction PACAP modulates reproductive functions and intervenes in the 
regulation of fertility. 
Mortality is high among PAC1 or PACAP knockout mice and reaches 
60% at one month of age. These mice have severe metabolic disorders 
and reduced mating and maternal behaviors.
Köves K, Szabó E, Kántor O, et al. Current state of understanding of the 
role of PACAP in the hypothalamo-hypophyseal gonadotropin 
functions of mammals. Front Endocrinol. 2020;11:88.
Thermogenesis PACAP plays a fundamental role in thermogenesis for the defense of 
body temperature
Cline DL, Short LI, Forster MAM, et al. Adipose tissue expression of 
PACAP, VIP, and their receptors in response to cold stress. J Mol 
Neurosci. 2019;68:427–438.
Obesity Leptin and PACAP collaborate together for maintaining normal energy 
homeostasis and body weight.
Hurley MM, Anderson EM, Chen C, et al. Acute blockade of PACAP- 
dependent activity in the ventromedial nucleus of the hypothalamus 
disrupts leptin-induced behavioral and molecular changes in rats. 
Neuroendocrinology. 2020;110:271–281.
Eating PACAP suppresses the intake of food, nicotine and alcohol. Gargiulo AT, Curtis GR, Barson JR. Pleiotropic pituitary adenylate 
cyclase-activating polypeptide (PACAP): novel insights into the role 
of PACAP in eating and drug intake. Brain Research. 
2020;1729:146,626.
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In our opinion, literature is also lacking regarding the 
examination of the potential advantages of anti-PACAP anti-
bodies, compared to those of antibodies against CGRP or its 
receptor. Indeed, the relationship between CGRP and PACAP 
in migraine remains undefined, even if PACAP is co-localized 
with CGRP in the TG and in the TNC [59]. Both PACAP 38 and 
CGRP induce migraine attacks, although not in all patients 
[43]. Considering that PACAP and CGRP have overlapping 
effects, it is not clear why blocking PACAP should be more 
effective or advantageous compared to the antagonism of 
CGRP. It has been suggested that PACAP38 could cause 
migraine independently of CGRP [68], as intravenous infusion 
of PACAP38 does not cause an increase in CGRP blood levels 
[43]. On this basis, anti-PACAP antibodies could perhaps be 
useful to patients who do not respond to anti CGRP drugs [20].
We think that the first task of research today is to clarify 
all the still undefined aspects of the role of PACAP in 
migraine and to allow clinical development to proceed. If 
anti-PACAP antibodies are available for therapeutic use, it 
will be interesting to study whether there are differences, 
and which, between the blockade of the PAC1 receptor and 
that of PACAP. Furthermore, anti-PACAP antibodies should 
compete with anti-CGRP drugs, which, in the meantime, are 
proving effective and safe in the short term, also in the real 
world. However, their long-term safety is still under evalua-
tion [69]. On the other hand, if anti-PACAP antibodies are 
shown to be ineffective and risky for prevention, the devel-
opment of an antagonist of the peptide or its PAC1 receptor 
for acute treatment may be attempted. A temporary block-
age of PACAP or PAC1 receptor could perhaps prove safe 
and effective.
Finally, to obtain results easily applicable to clinic, in our 
opinion it is necessary to find biomarkers (through neuroima-
ging, proteomics, metabolomics, etc.) to be integrated into 
clinical trials that can help identify the right migraine patients 
for one drug in the early phase of development. If all efforts of 
researchers and clinicians are completed, a ‘precision medi-
cine’ approach [70] may therefore be possible in the future, for 
the benefit of every migraine patient.
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